Cabotegravir/rilpivirine

New Novotech Report Finds 1,000 HIV Clinical Trials Globally

Retrieved on: 
Friday, December 29, 2023
Islatravir, Gene editing, Death, Drug development, CRISPR, Mortality, HIV, ROW, Investment, Cabotegravir/rilpivirine, Pharmaceutical industry

According to the HIV Global Clinical Trial Landscape report, the biopharma industry has initiated over 1,000 HIV clinical trials worldwide since 2018.

Key Points: 
  • According to the HIV Global Clinical Trial Landscape report, the biopharma industry has initiated over 1,000 HIV clinical trials worldwide since 2018.
  • Within Europe, Spain, France, the United Kingdom, Italy, and Germany attracted the most HIV trials.
  • Among the ROW countries, South Africa leads with 31% HIV trials.
  • Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023 and the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2022 and 2023 awards.

Injectable Drugs Global Market Report 2022: Featuring Amgen, Novo Nordisk, Pfizer, Novartis, Merck, GlaxoSmithKline & More - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Health, Pharmaceutical, Molecule, Eli Lilly and Company, Diet, Pfizer, Gilead Sciences, Rilpivirine, Johnson & Johnson, Type 2 diabetes, Geography, GIP, Novartis, Food, GSK plc, Amgen, Lonrho, Application, Baxter International, Marketing, FDA, Growth, US, Exercise, Novo Nordisk, U.S. FDA, Injection, Diabetes, Prevalence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, USFDA, COVID-19, Immunization, Fine chemical, Vaccine, Pharmaceutical industry, Cabotegravir/rilpivirine

Injectable drugs are used to treat wide variety of diseases and disorders.

Key Points: 
  • Injectable drugs are used to treat wide variety of diseases and disorders.
  • It profiles key players in the global injectable drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • The global injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global injectable drugs market.

ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg

Retrieved on: 
Tuesday, March 29, 2022
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Janssen Pharmaceuticals, GlaxoSmithKline, ViiV Healthcare, Population, Insomnia, Caregiver, Pfizer, Drug, Food, Rilpivirine, IMPAACT, Cabotegravir, HIV-1, US Foods, Adolescence, Injection site reaction, HIV, FDA, Hypersensitivity, Johnson & Johnson, Pharmaceutical industry, Vaccine, Cabotegravir/rilpivirine, CABENUVA (CABOTEGRAVIR, RILPIVIRINE), MOCHA/IMPAACT 2017

This approval marks the first time a long-acting HIV treatment is available for the adolescent population, underscoring ViiV Healthcares commitment to delivering options for young people living with HIV.

Key Points: 
  • This approval marks the first time a long-acting HIV treatment is available for the adolescent population, underscoring ViiV Healthcares commitment to delivering options for young people living with HIV.
  • Cabenuva is the first and only complete long-acting HIV treatment regimen and is approved as a once monthly or every-two-months treatment for HIV-1 in virologically suppressed adults and adolescents.
  • The efficacy of Cabenuva in adolescents is extrapolated from adults with support from pharmacokinetic analyses showing similar drug exposure.
  • INSTIs inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells).

CUNY SPH and the NYC Health Department to study long-acting antiretroviral therapy for HIV

Retrieved on: 
Monday, August 23, 2021
NIMH, Ryan White, Human services, National Institutes of Health, Science, Health policy, Survival, EHE, New York City Department of Health and Mental Hygiene, Mental health, Research, White, Health, St. John's Leprosy and HIV Care Services, Ryan, Public health, Office of Inspector General, U.S. Department of Health and Human Services, Implementation Science, Mental Hygiene, HIV/AIDS denialism, National, Partnership, Ebola virus disease treatment research, HIV, Population health, Los Angeles Police Department Mental Evaluation Unit, Graduate Center, CUNY, National Institute, Cabotegravir/rilpivirine, National Institute of Mental Health, CUNY, Pharmaceutical industry

NEW YORK, Aug. 23, 2021 /PRNewswire/ -- The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the New York City Department of Health and Mental Hygiene (NYC Health Department) a thirty-month grant to support long-acting injectable antiretroviral therapy access, uptake, and adherence among people with HIV enrolled in the Ryan White HIV/AIDS Program (hereafter "Ryan White").

Key Points: 
  • NEW YORK, Aug. 23, 2021 /PRNewswire/ -- The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the New York City Department of Health and Mental Hygiene (NYC Health Department) a thirty-month grant to support long-acting injectable antiretroviral therapy access, uptake, and adherence among people with HIV enrolled in the Ryan White HIV/AIDS Program (hereafter "Ryan White").
  • This project aligns with the "Treatment" pillar from the U.S. Department of Health and Human Services Ending the HIV Epidemic (EHE) initiative and with two of the National Institutes of Health's priorities: reducing health disparities and implementation research on new HIV treatments.
  • Although HIV treatment advances have improved health and survival for people living with HIV in New York, racial/ethnic, age-related, geographic, and other disparities in viral suppression remain.
  • "But it is critically important to find out quickly, to optimize the public health impact of these advances."

 ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months

Retrieved on: 
Wednesday, February 24, 2021
Research, Infectious diseases, Hospitals, FDA, Clinical trials, Biotechnology, AIDS, Pharmaceutical, Health, Science, Integrase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Drugs, Chemical compounds, Nitriles, Pyrimidines, Rilpivirine, Cabotegravir/rilpivirine, Organic compounds, Cabotegravir, ViiV Healthcare, Injection, Cabenuva (cabotegravir, rilpivirine), ViiV Healthcare, GSK

Cabenuva is a complete long-acting regimen with two separate injectable medicines, ViiV Healthcares cabotegravir and rilpivirine, a product of Janssen Sciences Ireland UC.

Key Points: 
  • Cabenuva is a complete long-acting regimen with two separate injectable medicines, ViiV Healthcares cabotegravir and rilpivirine, a product of Janssen Sciences Ireland UC.
  • The medication was approved by the FDA in January 2021 as a once monthly treatment for HIV-1 infection in virologically suppressed adults.
  • At ViiV Healthcare, we will continue to advance new approaches to care as part of our mission of leaving no person living with HIV behind.
  • Cabenuva is administered as two intramuscular injections (cabotegravir, rilpivirine) in the buttocks during the same visit by a healthcare professional.